{
  "id": 10578109,
  "title": "Celltrion Steps Up Global Partnering Push at CPHI 2026",
  "url": "https://urgent.news/2026/09/29/celltrion-steps-up-global-partnering-push-at-cphi-2026",
  "topic": "tech",
  "section": "Tech",
  "published": "2026-09-29T01:38:53.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=157593"
  },
  "original_language": "en",
  "account": "Celltrion is intensifying its global partnership initiatives at the upcoming CPHI 2026 exhibition in Milan, expanding beyond its biosimilar focus. The South Korean biopharmaceutical firm will take part in the three-day event from October 6 to 8, hosting a 46-pyeong booth with meeting rooms and a lounge. Celltrion aims to explore collaborations in novel drug development, contract manufacturing, and pharmaceutical supply chains. The company plans to identify global partners in oncology, obesity, metabolic disorders, and autoimmune diseases to bolster its next-generation pipeline. In addition to biosimilars, Celltrion seeks to diversify its growth drivers by strengthening supply chain resilience and tapping into the growing demand for contract development and manufacturing organization (CDMO) services. The exhibition, expected to gather over 60,000 industry professionals from more than 170 countries, will provide Celltrion with a platform to showcase its drug development and manufacturing capabilities and explore customized partnerships with global pharmaceutical companies.",
  "summary": "Celltrion is stepping up efforts to broaden its global business portfolio beyond biosimilars, using the upcoming CPHI 2026 exhibition in Milan as a platform to pursue partnerships in novel drug development, contract manufacturing and pharmaceutical supply chains.The South Korean biopharmaceutical co",
  "key_points": [
    "Celltrion intensifies global partnerships at CPHI 2026 in Milan.",
    "The company hosts a 46-pyeong booth with meeting rooms and lounge.",
    "Focus areas include novel drug development, contract manufacturing, and supply chain resilience."
  ],
  "editors_take": "Celltrion's expanded global partnership push at CPHI 2026 signals a strategic shift to diversify growth drivers beyond biosimilars, targeting novel drug development and CDMO services to strengthen its pipeline.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}